Core Viewpoint - Pfizer reported mixed first-quarter results for 2025, with adjusted earnings per share of 92 cents exceeding estimates but revenues of $13.72 billion falling short of expectations, reflecting a year-over-year decline of 8% [1][2][15]. Revenue Performance - Total revenues were $13.72 billion, down 8% year-over-year, missing the Zacks Consensus Estimate of $13.89 billion, with operationally a decrease of 6% and a negative currency impact of 2% [2]. - International revenues increased by 4% operationally to $5.34 billion, while U.S. revenues declined by 12% to $8.37 billion [3]. Product Segment Analysis - Primary Care segment sales fell 20% operationally to $5.7 billion, with Eliquis sales declining 4% to $1.92 billion due to pricing pressures from the Inflation Reduction Act [4][5]. - Specialty Care sales rose 6% to $4.0 billion, driven by Vyndaqel family revenues increasing by 33% to $1.49 billion [4][10]. - Oncology sales increased by 7% to $3.76 billion, with Padcev sales rising 25% to $426 million, while Ibrance revenues declined by 6% to $977 million [4][12][13]. Key Product Performance - Paxlovid revenues dropped 75% year-over-year to $491 million, missing estimates [8]. - Comirnaty sales rose 62% year-over-year to $565 million, exceeding expectations [7]. - The RSV vaccine, Abrysvo, recorded sales of $131 million, down 6% year-over-year, missing estimates [9]. Cost Management - Adjusted selling, informational, and administrative expenses decreased by 12% to $3.01 billion, while adjusted R&D expenses also fell by 12% to $2.17 billion [3]. 2025 Guidance - Pfizer reaffirmed its 2025 guidance, projecting total revenues between $61.0 billion and $64.0 billion, with adjusted earnings per share expected in the range of $2.80 to $3.00 [14][16]. Market Context - Pfizer's stock has declined 11.7% year-to-date, contrasting with a 1.5% increase in the industry [16]. - The company faces challenges from declining COVID-19 product sales and potential patent expirations impacting key products from 2026 to 2030 [17]. Strategic Outlook - Pfizer anticipates that non-COVID drug sales and new product contributions will drive revenue growth in 2025, alongside cost-cutting measures expected to yield savings of $7.7 billion by the end of 2027 [20].

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 250 points on Tuesday.The Dow traded up 0.70% to 40,507.41 while the NASDAQ rose 0.30% to 17,417.49. The S&P 500 also rose, gaining, 0.37% to 5,548.98.Check This Out: Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2Leading and Lagging SectorsMaterials shares jumped by 0.6% on Monday.In trading on Monday, consumer discretionary fell by 0.5%.Top HeadlineShares of Pfizer Inc. PFE gained around 3% on Tuesday ...

Francesca DeMartino Chief Investor Relations Officer, Senior Vice President First Quarter 2025 Earnings Teleconference April 29, 2025 1 Introduction First Quarter 2025 Earnings 2 Forward-Looking Statements and Non-GAAP Financial Information First Quarter 2025 Earnings 3 • Our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statem ...

Pfizer (PFE) Q1 2025 Earnings Call April 29, 2025 10:00 AM ET Company Participants Francesca DeMartino - SVP & Chief Investor Relations OfficerAlbert Bourla - Chairman & CEODave Denton - EVP & CFOAamir Malik - Executive VP & Chief U.S. Commercial OfficerAlexandre de Germay - Executive VP & Chief International Commercial OfficerChris Boshoff - Chief Scientific Officer and President, Research & DevelopmentAndrew Baum - Chief Strategy & Innovation Officer, Executive VPUmer Raffat - Senior Managing DirectorChri ...

Pfizer (PFE) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 43.75%. A quarter ago, it was expected that this drugmaker would post earnings of $0.48 per share when it actually produced earnings of $0.63, delivering a surprise of 31.25%.Over the last four quarters, the company has surp ...

Core Viewpoint - Pfizer's Q1 earnings report shows a decline in overall revenue despite cost-cutting measures and better-than-expected profits, primarily due to setbacks in its weight-loss drug development and decreased revenue from COVID-related products [1][2]. Group 1: Financial Performance - Pfizer reported Q1 revenue of $13.72 billion, an 8% year-over-year decline, falling short of the analyst consensus of $13.91 billion [1]. - The company's net profit for Q1 was $2.97 billion, or $0.52 per share, compared to $3.12 billion, or $0.55 per share, in the same period last year; adjusted EPS was $0.92, exceeding the average analyst estimate of $0.66 [1]. - Pfizer maintains its full-year 2025 revenue outlook between $61 billion and $64 billion, with adjusted EPS expectations of $2.80 to $3.00, despite external pressures from potential tariffs on imported drugs [4]. Group 2: Cost-Cutting Initiatives - Following the failure of its weight-loss drug Danuglipron, Pfizer is expanding its cost-cutting plans, aiming for an additional $1.2 billion in savings by the end of 2027, primarily from reductions in sales, information, and administrative expenses [2]. - The company previously announced a cost-cutting plan targeting $4.5 billion in net savings by the end of 2025, with an additional $500 million expected to be saved through research and organizational restructuring by the end of 2026 [2][3]. - Pfizer's independent multi-year cost reduction plan aims to save $1.5 billion by the end of 2027, helping the company recover from the rapid decline in COVID-related business and stock price [3]. Group 3: Market Outlook and Challenges - Pfizer's decision to abandon the development of Danuglipron has led to adjustments in market forecasts for weight-loss drugs, with Goldman Sachs removing Pfizer's projections for the drug from their models, previously estimating sales of $1.2 billion and $1.9 billion for 2030 and 2035, respectively [1]. - The company anticipates that the Inflation Reduction Act will reduce its sales by $1 billion, with a projected growth rate decrease of approximately 1.6% compared to 2024 [4]. - CEO Albert Bourla expressed confidence in the company's ability to adapt to uncertain external conditions, emphasizing the inherent strengths of its business [4].

Financial Performance - First-quarter 2025 revenues totaled $13.7 billion, a decrease of 8% compared to $14.9 billion in the prior-year quarter[5] - Reported diluted EPS for the first quarter of 2025 was $0.52, down 5% from $0.55 in the same quarter of 2024, while adjusted diluted EPS increased by 12% to $0.92[5][4] - The global biopharmaceuticals business reported revenues of $13.4 billion, an 8% decline from $14.6 billion in the previous year[6] - The company reaffirmed its full-year 2025 financial guidance, projecting revenues between $61.0 billion and $64.0 billion and adjusted diluted EPS between $2.80 and $3.00[7] - Total revenues for Q1 2025 were $13.715 billion, a decrease of 8% compared to $14.879 billion in Q1 2024[26] - Product revenues decreased by 9% to $11.294 billion in Q1 2025 from $12.443 billion in Q1 2024[26] - Alliance revenues were $2.113 billion, down 3% from $2.172 billion in the previous year[26] - Net income attributable to Pfizer Inc. common shareholders was $2.967 billion, a decrease of 5% from $3.115 billion in Q1 2024[26] - Earnings per share (EPS) for Q1 2025 were $0.52, down 5% from $0.55 in Q1 2024[26] - Total revenues for 2025 were $13,715 million, a decrease of 8% compared to 2024[43] Cost Savings and Efficiency - Pfizer is on track to achieve approximately $4.5 billion in net cost savings by the end of 2025, with additional productivity gains expected through 2027[4] - Pfizer announced approximately $1.2 billion in additional anticipated savings from its ongoing cost realignment program, expected to be achieved by the end of 2027[19] - The company expects total net cost savings of approximately $5.7 billion from the cost realignment program through 2027[19] - Pfizer expects approximately $4.5 billion in net cost savings from its ongoing cost realignment program by the end of 2025[4] - The company expects one-time costs to achieve additional savings to total approximately $1.6 billion, primarily for severance and digital enablement[19] Research and Development - R&D expenses for the first quarter of 2025 were $2.2 billion, a decrease of 12% compared to the prior year, reflecting a focus on pipeline optimization[12] - Research and development expenses decreased by 12% to $2.203 billion in Q1 2025 from $2.493 billion in Q1 2024[26] - The Phase 3 CREST trial of sasanlimab showed a 32% reduction in the risk of disease-related events compared to standard of care in high-risk non-muscle invasive bladder cancer patients[18] - The Phase 3 VERITAC-2 trial demonstrated a statistically significant improvement in progression-free survival for vepdegestrant compared to fulvestrant in the ESR1m population[18] Product Performance - Paxlovid revenues decreased by 75% year-over-year, primarily due to lower COVID-19 infections and the non-recurrence of a favorable adjustment from the previous year[13] - Vyndaqel family revenues increased by 33% operationally, driven by strong demand in the U.S. and international markets[11] - Primary Care revenues fell by 21% to $5,696 million, with significant declines in key products like Paxlovid, which dropped 76% to $491 million[43] - Specialty Care revenues increased by 4% to $3,987 million, driven by the Vyndaqel family, which saw a 31% increase to $1,486 million[43] - Oncology revenues rose by 6% to $3,758 million, with Ibrance revenues decreasing by 7% to $977 million[43] - Total alliance revenues decreased by 3% to $2,113 million, while total royalty revenues increased by 16% to $308 million[43] Tax and Income - The effective tax rate on adjusted income for the first quarter of 2025 was 7.8%, down from 16.6% in the prior year[15] - The effective tax rate for income from continuing operations was -6.8% in Q1 2025, compared to 8.6% in Q1 2024[32] - GAAP reported net income for Q1 2025 was $953 million, a decrease from $3,115 million in Q1 2024, representing a decline of approximately 69%[37] - Non-GAAP adjusted net income for Q1 2025 was $5,237 million, compared to $4,674 million in Q1 2024, indicating an increase of about 12%[37] - Earnings per share attributable to Pfizer Inc. common shareholders for Q1 2025 was $0.92, up from $0.82 in Q1 2024, reflecting a growth of approximately 12%[37] Strategic Initiatives and Risks - Pfizer's acquisition of Seagen in December 2023 is expected to enhance growth opportunities and market presence[48] - The company is implementing a Manufacturing Optimization Program aimed at reducing costs and improving efficiency[48] - Pfizer's financial guidance remains subject to significant uncertainties, including regulatory approvals and market dynamics[49] - The company faces risks related to competition from new product entrants, generic products, and biosimilars, which could impact revenue growth[50] - There are uncertainties regarding the demand for COVID-19 products, which may lead to reduced revenues and excess inventory[50] - The company is exposed to fluctuations in interest rates and foreign currency exchange rates, which could affect financial performance[50] - Significant issues with major wholesale distributors or government customers could impact a substantial portion of revenues[50] - The company is at risk of legal and regulatory challenges that may affect product pricing and access, particularly in the U.S. and international markets[53] - The potential impact of climate change and natural disasters on operations is a concern for the company[53] - The company is undertaking corporate strategic initiatives that may require upfront costs but could yield unexpected consequences[53] - There are risks associated with the company's ability to achieve climate-related goals and progress in environmental sustainability[53] - The company is facing challenges related to cybersecurity threats, including potential cyber-attacks and data breaches[57] - The company is involved in collaborations for co-research and co-development of products, which may vary by market[56]

Core Viewpoint - Pfizer has experienced significant stock price declines since its peak in late 2021, primarily due to reduced sales of its COVID-19 treatments and vaccines, but it still holds potential for future growth, particularly in oncology and offers an attractive dividend yield [2][4][5] Group 1: Stock Performance - Pfizer's stock has seen over a 60% decline from its late-2021 high, with a $10,000 investment from 10 years ago now worth just over $7,000 [2] - Including reinvested dividends, the investment would be worth approximately $10,600 over the same period, although this still lags behind broader market returns [3] Group 2: Sales and Market Reaction - The decline in stock value is largely attributed to slowing sales of its COVID-19 treatment Paxlovid and vaccine Comirnaty, with no compensating growth from other products in its portfolio [4] Group 3: Future Outlook - Despite recent setbacks, there are new growth prospects for Pfizer, especially in oncology, and the stock's forward-looking dividend yield of 7.5% may attract new investors confident in the company's future [5]

智通财经4月29日电，辉瑞公司重申2025年全年财务指引的所有组成部分，包括610亿美元至640亿美元 的收入和2.80美元至3.00美元的调整后摊薄后每股收益。 ...

Pfizer Inc. PFE will release earnings results for the first quarter, before the opening bell on Tuesday, April 29. Analysts expect the New York-based company to report quarterly earnings at 68 cents per share, down from 82 cents per share in the year-ago period. Pfizer projects to report quarterly revenue at $14.09 billion, compared to $14.88 billion a year earlier, according to data from Benzinga Pro. Guardant Health GH, on April 24, announced a strategic collaboration with Pfizer to support the developmen ...